These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21912084)

  • 1. Hypocalcemia associated with zoledronic acid for osteogenesis imperfecta.
    Das RR
    Horm Res Paediatr; 2011; 76(4):291; author reply 292. PubMed ID: 21912084
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Therapies for Osteogenesis Imperfecta.
    Sousa S; Godinho F; Santos MJ
    Acta Med Port; 2017 Feb; 30(2):156-157. PubMed ID: 28527487
    [No Abstract]   [Full Text] [Related]  

  • 3. Zolendronate in osteogenesis imperfecta.
    Panigrahi I; Das RR; Marwaha RK
    J Pediatr Endocrinol Metab; 2009 Aug; 22(8):763. PubMed ID: 19845128
    [No Abstract]   [Full Text] [Related]  

  • 4. [Zoledronic acid (zoledronate) in children with osteogenesis imperfecta].
    Sánchez-Sánchez LM; Cabrera-Pedroza AU; Palacios-Saucedo G; de la Fuente-Cortez B
    Gac Med Mex; 2015; 151(2):164-8. PubMed ID: 25946526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of zoledronic acid in adults with osteogenesis imperfecta].
    Pavón de Paz I; Iglesias Bolaños P; Durán Martínez M; Olivar Roldán J; Guijarro De Armas G; Parra García JI
    Endocrinol Nutr; 2010; 57(6):245-50. PubMed ID: 20510658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children.
    Kumar C; Panigrahi I; Somasekhara Aradhya A; Meena BL; Khandelwal N
    J Pediatr Endocrinol Metab; 2016 Aug; 29(8):947-52. PubMed ID: 27235668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteogenesis imperfecta and bisphosphonates].
    Forin V
    Arch Pediatr; 2005 Jun; 12(6):688-90. PubMed ID: 15904772
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonates in osteogenesis imperfecta.
    Shaw NJ
    Arch Dis Child; 1997 Jul; 77(1):92-3. PubMed ID: 9279168
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteogenesis imperfecta--managing brittle bones.
    Marini JC
    N Engl J Med; 1998 Oct; 339(14):986-7. PubMed ID: 9753715
    [No Abstract]   [Full Text] [Related]  

  • 14. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
    Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
    Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the benefits of pamidronate in children with osteogenesis imperfecta.
    Lindsay R
    J Clin Invest; 2002 Nov; 110(9):1239-41. PubMed ID: 12417561
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Fujiwara I; Ogawa E; Igarashi Y; Ohba M; Asanuma A
    Eur J Pediatr; 1998 Mar; 157(3):261-2. PubMed ID: 9537501
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A; Munns CF
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shin splints: an unexpected effect of bisphosphonates in osteogenesis imperfecta.
    Balink H
    Clin Nucl Med; 2009 Feb; 34(2):87-8. PubMed ID: 19352259
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate-lessons from biochemistry.
    Langman CB
    J Clin Endocrinol Metab; 2003 Mar; 88(3):984-5. PubMed ID: 12629072
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions.
    Brizola E; Shapiro JR
    Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.